TIDMCLL

RNS Number : 2122W

Cello Health PLC

15 April 2019

15 April 2019

Cello Health plc

("Cello" or the "Group")

Annual Report and Notice of AGM

Cello Health plc (AIM: CLL), the healthcare-led advisory group, announces that it is today posting to shareholders its annual report and accounts for the year ended 31 December 2018 (the "2018 Accounts") together with the notice of Annual General Meeting ("AGM").

Copies of the 2018 Accounts, and the notice of AGM, are available to view on the Company's website, https://cellohealthplc.com.

The AGM will be held at the offices of Buchanan, 107 Cheapside, London, EC2V 6DN, at 12.30pm on Wednesday 8 May 2019.

Enquiries:

 
  Cello Health plc                             020 7812 8460 
  Mark Scott, Chief Executive 
  Mark Bentley, Group Finance Director 
 
  Cenkos Securities (Nominated adviser and 
   broker)                                     020 7397 8900 
  Mark Connelly 
  Harry Hargreaves 
 
  Buchanan                                     020 7466 5000 
  Mark Court 
  Jamie Hooper 
  Sophie Wills

About Cello Health plc

Cello Health plc is a global healthcare-focused advisory Group comprised of a set of leading clinical, commercial advisory and digital delivery capabilities. Cello Health plc currently services 24 of the top 25 pharmaceutical clients globally, as well as a wide range of biotech, diagnostics, devices and other key non-healthcare clients.

Cello Health plc enables clients to commercialise and differentiate their assets and drive brand success in ever more complex global markets. The business delivers its services through nearly 1,000 highly skilled professionals, utilising latest thinking, technology and digital solutions.

Cello Health plc delivers its services from an office network in the UK, USA, and Asia, with hub offices in New York City, Philadelphia PA, London, Edinburgh, Farnham and Cheltenham.

For further information, please visit: https://cellohealthplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

ACSEAELSFEXNEFF

(END) Dow Jones Newswires

April 15, 2019 06:12 ET (10:12 GMT)

Cello Health (LSE:CLL)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Cello Health Charts.
Cello Health (LSE:CLL)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Cello Health Charts.